Shinobu Kawakatsu

Shinobu Kawakatsu

Auto-generated profile, based on publicly available information

Shinobu Kawakatsu

Department of Neuropsychiatry, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
HMHiroshi Matsuda
Hiroshi Matsuda
KYKota Yokoyama
Kota Yokoyama
NSNoriko Sato
Noriko Sato
KIKengo Ito
Kengo Ito
KNKiyotaka Nemoto
Kiyotaka Nemoto
KSKeiko Shigemori
Keiko Shigemori
Background: The differential diagnosis of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) is particularly important because DLB patients respond better to cholinesterase inhibitors but sometimes exhibit sensitivity to neuroleptics, which may cause worsening of clinical status. Antemortem voxel-based morphometry (VBM) using structural MRI has previously revealed that patients with DLB have normal hippocampal volume, but atrophy in the dorsal mesopontine area. Objectives: The aim of this multicenter study was to determine whether VBM of the brain stem in addition to that of medial temporal lobe structures improves the differential diagnosis of AD and DLB. Methods: We retrospectively chose 624 patients who were clinically diagnosed with either DLB (239 patients) or AD (385 patients) from 10 institutes using different MR scanners with different magnetic field strengths. In all cases, VBM was performed on 3D T1-weighted images. The degree of local atrophy was calculated using Z-score by comparison with a database of normal volumes of interest (VOIs) in medial temporal lobe (MTL) and the dorsal brain stem (DBS). The discrimination of DLB and AD was evaluated using Z-score values in these two VOIs. MRI data from 414 patients were used as the training data set to determine the classification criteria, with the MRI data from the remaining 210 patients used as the test data set. Results: The DLB and AD patients did not differ with respect to mean age or Mini-Mental State Examination scores. Z-index scores showed that there was significantly more atrophy in MTL of AD patients, compared to DLB patients and in DBS of DLB patients, compared to AD patients. The discrimination accuracies of VBM were 63.3% in the test data set and 73.4% in the training data set. Conclusion: VBM of DBS in addition to that of MTL improves the differentiation of DLB and AD.

21 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKShingo Koyama
Shingo Koyama
HSHidenori Sato
Hidenori Sato
RKRyota Kobayashi
Ryota Kobayashi
SKShinobu Kawakatsu
Shinobu Kawakatsu
MKMasayuki Kurimura
Masayuki Kurimura
TKTakeo Kato
Takeo Kato
Primary familial brain calcification (PFBC) is a rare neuropsychiatric disorder with characteristic symmetrical brain calcifications. Patients with PFBC may have a variety of symptoms, although they also may be clinically asymptomatic. Parkinsonism is one of the most common movement disorders; however, the underlying mechanism remains unclear. This condition is typically transmitted in an autosomal dominant fashion. To date, mutations in SLC20A2, PDGFRB, PDGFB, and XPR1 have been reported to cause PFBC. The aim of the study was to identify the genetic cause of brain calcification in probands from three PFBC families and in 8 sporadic patients and to perform clinical and radiological assessments focusing on parkinsonism in mutation carriers. Three familial PFBC probands and their relatives and eight sporadic patients affected with brain calcifications were enrolled in this study. Whole-exome sequencing identified three novel mutations: c.269G > T, p.(Gly90Val) and c.516+1G > A in SLC20A2 in familial cases, and c.602-1G > T in PDGFB in a sporadic patient. The c.516+1G > A mutation resulted in exon 4 skipping in SLC20A2 (p.Val144Glyfs*85). Dopamine transporter single photon emission computed tomography using 123I-ioflupane and 123I-metaiodobenzylguanidine cardiac scintigraphy revealed pre-synaptic dopaminergic deficit and cardiac sympathetic nerve dysfunction in two SLC20A2-related PFBC patients with parkinsonism.

23 November 2021 in Neuropathology
Verified
Journal Article
Closed access
PDF file
SKShinobu Kawakatsu
Shinobu Kawakatsu
RKRyota Kobayashi
Ryota Kobayashi
HHHiroshi Hayashi
Hiroshi Hayashi
DMDaichi Morioka
Daichi Morioka
AUAya Utsunomiya
Aya Utsunomiya
KOKoichi Otani
Koichi Otani


22 February 2023 in Psychogeriatrics
Verified
Journal Article
Closed access
AEAyako Edahiro
Ayako Edahiro
Tsuyoshi OkamuraTsuyoshi Okamura
Tsuyoshi Okamura
TATETSUAKI ARAI
TETSUAKI ARAI
TITakeshi Ikeuchi
Takeshi Ikeuchi
MIManabu Ikeda
Manabu Ikeda
SAShuichi Awata
Shuichi Awata

7 March 2023 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
PDF file
RKRyota Kobayashi
Ryota Kobayashi
TNTadaho Nakamura
Tadaho Nakamura
FNFumito Naganuma
Fumito Naganuma
RHRyuichi Harada
Ryuichi Harada
DMDaichi Morioka
Daichi Morioka
NONobuyuki Okamura
Nobuyuki Okamura
Quantification of in vivo reactive astrogliosis, which represents neural inflammation and remodeling in the brain, is an emerging methodology for the evaluation of patients with neurodegenerative diseases. [18F]THK-5351 is a positron emission tomography (PET) tracer for monoamine oxidase B (MAO-B), a molecular marker of reactive astrogliosis. We performed in vivo [18F]THK-5351 PET in a patient who at autopsy was found to have argyrophilic grain disease (AGD) with comorbid pathology to visualize reactive astrogliosis for the first time. We aimed to validate an imaging-pathology correlation using [18F]THK-5351 PET and the autopsy brain. The patient, a 78-year-old man, was pathologically diagnosed with AGD combined with limbic-predominant age-related transactive response DNA-binding protein of 43 kDa encephalopathy and Lewy body disease without Alzheimer disease-related neuropathological changes. Reactive astrogliosis in the postmortem brain was abundant in the inferior temporal gyrus, insular gyrus, entorhinal cortex, and ambient gyrus where premortem [18F]THK-5351 signals were high. We found a proportional correlation between the amount of reactive astrogliosis in the postmortem brain and the in vivo [18F]THK-5351 standardized uptake value ratio (r = 0.8535, p = 0.0004). These results indicated that reactive astrogliosis in AGD with comorbid pathology could be identified and quantified by in vivo MAO-B imaging.